TIPS for Portal Hypertension in HCC With Tumour Invasion of the Portal Vein Trunk: Anecdote or Promise?

Abstract:

Keywords:

References: Reig M., Forner A., Rimola J., et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022 Mar;76:681–693.
Garcia-Tsao G., Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010 Mar 4;362:823–832.
Kaplan D.E., Bosch J., Ripoll C., et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2023 Oct 23 doi: 10.1097/HEP.0000000000000647.
de Franchis R., Bosch J., Garcia-Tsao G., Reiberger T., Ripoll C., Baveno VII Faculty Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022 Apr;76:959–974.
D'Amico G., Pasta L., Morabito A., et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014 May;39:1180–1193.
Bruix J., Castells A., Bosch J., Feu F., Fuster J. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996 Oct;111:1018–1022.
Berzigotti A., Reig M., Abraldes J.G., Bosch J., Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology. 2015 Feb;61:526–536.
Ripoll C., Genescà J., Araujo I.K., et al. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology. 2013 Dec;58:2079–2088. doi: 10.1002/hep.26629. Epub 2013 Oct 15. PMID: 23908019.
Balcar L., Mrekva A., Scheiner B., et al. Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion. Cancer Imag. 2024;24:9.
Senzolo M., Shalaby S., Grasso A., et al. Role of nonneoplastic PVT in the natural history of patients with cirrhosis and first diagnosis of HCC. Hepatology. 2024;79:355–367.
Allaire M., Thabut D. Portal hypertension and variceal bleeding in patients with liver cancer: evidence gaps for prevention and management. Hepatology. 2024 Jan 1;79:213–223.
Thabut D., Kudo M. Treatment of portal hypertension in patients with HCC in the era of Baveno VII. J Hepatol. 2023 Mar;78:658–662.
Bosch J. Small diameter shunts should lead to safe expansion of the use of TIPS. J Hepatol. 2021 Jan;74:230–234.
Qiu Z., Wang G., Yan H., et al. TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension. Eur Radiol. 2022;32:6777–6787.
Han H., Meng Y., Wang J. Effect of transjugular intrahepatic portosystemic shunt combined with 125I particle implantation on portal vein tumor thrombus in hepatocellular carcinoma. Am J Transl Res. 2022;14:1838–1848.
Xie Y., Lyu T., Song L., Tong X., Wang J., Zou Y. Transjugular intrahepatic portosystemic shunt for advanced hepatocellular carcinoma with main portal vein tumor thrombus-related symptomatic portal hypertension. J Clin Exper Hepatol. 2024;14:101305.
Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb 9;381:468–475.
Papatheodoridis G.V., Idilman R., Dalekos G.N., et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017 Nov;66:1444–1453.
Casado M., Bosch J., García-Pagán J.C., et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology. 1998 Jun;114:1296–1303.

Authors

• Jaime Bosch |